|
|
|
|
Genta commences Phase 2 trial of tesetaxel on first subject
Genta Incorporated (OTCBB: GETA) announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced melanoma.Tesetaxel is the Companys newest clinical-stage small molecule. As a late Phase 2 oncology...
|
|
|
Genta commences treatment in tesetaxel Phase 2 trial for advanced melanoma
Genta Incorporated (OTCBB: GETA) announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced melanoma.Tesetaxel is the Companys newest clinical-stage small molecule. As a late Phase 2 oncology...
|
|
|
Genta Initiates Phase 2 Study of Tesetaxel, the Leading Clinical-Stage Oral Taxane, in Patients with Advanced
- Genta Incorporated (OTCBB: GETA) announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced melanoma.Tesetaxel is the Company's newest clinical-stage small molecule. As a late Phase 2 oncology...
|
|
|
Genta Initiates Phase 2 Study of Tesetaxel, the Leading Clinical-Stage Oral Taxane, in Patients with Advanced
BERKELEY HEIGHTS, N.J.(BUSINESS WIRE) Genta Incorporated (OTCBB: GETA) announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced melanoma.Tesetaxel is the Company's newest clinical-stage small...
|
|
|
Genta Initiates Phase 2 Study of Tesetaxel, the Leading Clinical-Stage Oral Taxane, in Patients with Advanced Melanoma
BERKELEY HEIGHTS, N.J.-- (BUSINESS WIRE) -- Genta Incorporated (OTCBB: GETA) announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced melanoma.Tesetaxel is the Companys newest clinical-stage...
|
|
|
Genta Initiates Phase 2 Study of Tesetaxel, the Leading Clinical-Stage Oral Taxane, in Patients with Advanced Melanoma
Companies mentioned in this article: Genta Incorporated BERKELEY HEIGHTS, N.J.-- (BUSINESS WIRE) -- Genta Incorporated (OTCBB: GETA) announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced...
|
|
|
Genta Initiates Phase 2 Study of Tesetaxel, the Leading Clinical-Stage Oral Taxane, in Patients with Advanced
Companies mentioned in this article: Genta Incorporated BERKELEY HEIGHTS, N.J.-- (BUSINESS WIRE) -- Genta Incorporated (OTCBB: GETA) announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced...
|
|
|
Genta Initiates Phase 2 Study of Tesetaxel, the Leading Clinical-Stage Oral Taxane, in Patients with Advanced
Genta Incorporated (OTCBB: GETA) announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced melanoma.Tesetaxel is the Companys newest clinical-stage small molecule. As a late Phase 2 oncology...
|
|
|
EU clears Eurocor's coronary stent
FURTHER READING Company Eurocor Product paclitaxel Taxcor Plus Taxol Topic coronary artery trauma coronary interventions coronary stent polymer Portals Coronary Intervention Section Regulatory News addthis_pub The Taxcor Plus, a paclitaxel-eluting...
|
|
|
Children's Hospital Boston Researchers ID Protein That May Explain Paclitaxel Resistance
Researchers from Children's Hospital Boston have used a proteomics approach to identify a protein that may play a key role in determining why some patients fail to respond to one of the most successful cancer treatments in history.Described in a study...
|
|
|
Overcoming Taxane Resistance in Cancer
Proteomics study reveals a protein that, when suppressed, makes cancers more susceptible to chemotherapy BOSTON, Jan.25 /PRNewswire-USNewswire/ -- Taxanes, a group of cancer drugs that includes paclitaxel (Taxol) and docetaxel (Taxotere), have become...
|
|
|
Two Combination Treatment Regimens Added to Updated NCCN Guidelines for Ovarian Cancer
The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Guidelines for Ovarian Cancer to include two additional combination treatment regimens for women with select types of recurring ovarian cancer FORT WASHINGTON, Pa.--(BUSINESS WIRE)--Jan...
|
|
|
Protein may Help Overcome Taxane Resistance in Cancer Drugs: Discovery
Category: Drug News Font Size A protein involved in taxane resistance, a group of cancer drugs that includes paclitaxel (Taxol) and docetaxel (Taxotere) have been discovered by Scientists at Children's Hospital Boston, and has become front-line therapy...
|
|
|
Proteomics Study Reveals A Protein That, When Suppressed, Makes Cancers More Susceptible To Chemotherapy
Taxanes, a group of cancer drugs that includes paclitaxel (Taxol) and docetaxel (Taxotere), have become front-line therapy for a variety of metastatic cancers.But as with many chemotherapy agents, resistance can develop, a frequent problem in breast,...
|
|
|
Medical News: Proteomics Study Reveals A Protein That, When Suppressed, Makes Cancers More Susceptible To Chemotherapy
Taxanes, a group of cancer drugs that includes paclitaxel (Taxol) and docetaxel (Taxotere), have become front-line therapy for a variety of metastatic cancers.But as with many chemotherapy agents, resistance can develop, a frequent problem in breast,...
|
|
|
New discovery may help overcome taxane resistance in cancer
Washington DC: Scientists at Children's Hospital Boston have discovered a protein involved in taxane resistance, a group of cancer drugs that includes paclitaxel (Taxol) and docetaxel (Taxotere) and have become front-line therapy for a variety of...
|
|
|
New discovery may help overcome taxane resistance in cancer
Scientists at Children's Hospital Boston have discovered a protein involved in taxane resistance, a group of cancer drugs that includes paclitaxel (Taxol) and docetaxel (Taxotere) and have become front-line therapy for a variety of metastatic cancers.
|
|
|
Proteomics study reveals protein suppression makes cancers more susceptible to chemotherapy
Taxanes, a group of cancer drugs that includes paclitaxel (Taxol-) and docetaxel (Taxotere-), have become front-line therapy for a variety of metastatic cancers.But as with many chemotherapy agents, resistance can develop, a frequent problem in breast,...
|
|
|
Overcoming taxane resistance in cancer
Proteomics study reveals a protein that, when suppressed, makes cancers more susceptible to chemotherapy Taxanes, a group of cancer drugs that includes paclitaxel (Taxol) and docetaxel (Taxotere), have become front-line therapy for a variety of metastatic...
|
|
|
Overcoming taxane resistance in cancer
Taxanes, a group of cancer drugs that includes paclitaxel (Taxol(R)) and docetaxel (Taxotere(R)), have become front-line therapy for a variety of metastatic cancers.But as with many chemotherapy agents, resistance can develop, a frequent problem in breast,...
|
|
|
NCCN updates the NCCN Clinical Practice Guidelines for Oncology for Ovarian Cancer
The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Clinical Practice Guidelines for Oncology for Ovarian Cancer to reflect the addition of two preferred combination regimens for a specific cohort of patients based on data from recent...
|
|
|
Two Combination Treatment Regimens Added To Updated NCCN Guidelines For Ovarian Cancer
The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Clinical Practice Guidelines for Oncology for Ovarian Cancer to reflect the addition of two preferred combination regimens for a specific cohort of patients based on data from recent...
|
|
|
Overcoming Taxane Resistance In Cancer
Proteomics study reveals a protein that, when suppressed, makes cancers more susceptible to chemotherapy Taxanes, a group of cancer drugs that includes paclitaxel (Taxol) and docetaxel (Taxotere), have become front-line therapy for a variety of metastatic...
|
|
|
Overcoming taxane resistance in cancer
ScienceDaily (Jan.26, 2010) Taxanes, a group of cancer drugs that includes paclitaxel (Taxol) and docetaxel (Taxotere), have become front-line therapy for a variety of metastatic cancers. But as with many chemotherapy agents, resistance can develop,...
|
|
|
Overcoming taxane resistance in cancer
Taxanes, a group of cancer drugs that includes paclitaxel (Taxol) and docetaxel (Taxotere), have become front-line therapy for a variety of metastatic cancers.But as with many chemotherapy agents, resistance can develop, a frequent problem in breast,...
|
